US FDA approves Replimune's skin cancer drug after prior rejections
Reuters
The US FDA has approved Replimune's skin cancer drug, marking a reversal of its previous rejections. This decision highlights the agency's willingness to reconsider approvals based on new data or evidence. The approval allows patients with skin cancer access to this newly validated treatment option.
All articles from 7 August 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.